Literature DB >> 34097483

Efflux Pump Overexpression Profiling in Acinetobacter baumannii and Study of New 1-(1-Naphthylmethyl)-Piperazine Analogs as Potential Efflux Inhibitors.

Morgane Choquet1,2, Elodie Lohou1, Etienne Pair1, Pascal Sonnet1, Catherine Mullié1,2.   

Abstract

Overexpression of efflux pumps extruding antibiotics currently used for the treatment of Acinetobacter baumannii infections has been described as an important mechanism causing antibiotic resistance. The first aim of this work was to phenotypically evaluate the overexpression of efflux pumps on a collection of 124 ciprofloxacin-resistant A. baumannii strains. An overexpression of genes encoding one or more efflux pumps was obtained for 19 out of the 34 strains with a positive phenotypic efflux (56%). The most frequent genes overexpressed were those belonging to the RND family, with adeJ being the most prevalent (50%). Interestingly, efflux pump genes coding for MATE and MFS families were also overexpressed quite frequently: abeM (32%) and abaQ (26%). The second aim was to synthesize 1-(1-naphthylmethyl)-piperazine analogs as potential new efflux pump inhibitors and biologically evaluate them against strains with a positive phenotypic efflux. Quinoline and pyridine analogs were found to be more effective than their parent compound, 1-(1-naphthyl methyl)-piperazine. Stereochemistry also played an important part in the inhibitory activity, as quinoline derivative (R)-3a was identified as being the most effective and less cytotoxic. Its inhibitory activity was also correlated with the number of efflux pumps expressed by a strain. The results obtained in this work suggest that quinoline analogs of 1-(1-naphthylmethyl)-piperazine are promising leads in the development of new anti-Acinetobacter baumannii therapeutic alternatives in combination with antibiotics for which an efflux-mediated resistance is suspected.

Entities:  

Keywords:  Acinetobacter baumannii; antibiotic resistance; efflux pump; efflux pump inhibitors

Mesh:

Substances:

Year:  2021        PMID: 34097483      PMCID: PMC8370237          DOI: 10.1128/AAC.00710-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  58 in total

Review 1.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 2.  Waltzing transporters and 'the dance macabre' between humans and bacteria.

Authors:  Olga Lomovskaya; Helen I Zgurskaya; Maxim Totrov; William J Watkins
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

3.  Absolute Configuration and Antimalarial Activity of erythro-Mefloquine Enantiomers.

Authors:  Alexandra Dassonville-Klimpt; Christine Cézard; Catherine Mullié; Patrice Agnamey; Alexia Jonet; Sophie Da Nascimento; Mathieu Marchivie; Jean Guillon; Pascal Sonnet
Journal:  Chempluschem       Date:  2013-06-21       Impact factor: 2.863

4.  Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.

Authors:  Louis B Rice
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

5.  Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice.

Authors:  Luiz E Bermudez; Clark B Inderlied; Peter Kolonoski; Christopher B Chee; Priscilla Aralar; Mary Petrofsky; Toufan Parman; Carol E Green; Anita H Lewin; William Y Ellis; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 6.  Efflux-mediated antibiotic resistance in Acinetobacter spp.

Authors:  Sébastien Coyne; Patrice Courvalin; Bruno Périchon
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

7.  Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.

Authors:  O Lomovskaya; M S Warren; A Lee; J Galazzo; R Fronko; M Lee; J Blais; D Cho; S Chamberland; T Renau; R Leger; S Hecker; W Watkins; K Hoshino; H Ishida; V J Lee
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii.

Authors:  C Rumbo; E Gato; M López; C Ruiz de Alegría; F Fernández-Cuenca; L Martínez-Martínez; J Vila; J Pachón; J M Cisneros; J Rodríguez-Baño; A Pascual; G Bou; M Tomás
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

9.  Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains.

Authors:  Jacqueline Chevalier; Jérôme Bredin; Abdallah Mahamoud; Monique Malléa; Jacques Barbe; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Characteristics and diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with drug-resistant clinical isolates of Acinetobacter baumannii.

Authors:  Bahare Salehi; Zohreh Ghalavand; Abbas Yadegar; Gita Eslami
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-10       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.